Phase II Trial of Brentuximab Vedotin as First-Line Salvage Therapy in Relapsed/Refractory HL Prior to Autologous Stem Cell Transplant


Phase II Trial of Brentuximab Vedotin as First-Line Salvage Therapy in Relapsed/Refractory HL Prior to Autologous Stem Cell Transplant
Slides from a presentation at ASH 2014 and transcribed comments from a recent interview with Craig Moskowitz, MD (1/6/15)
Chen RW et al. Results of a Phase II trial of brentuximab vedotin as first line salvage therapy in relapsed/refractory Hodgkin lymphoma prior to autologous HCT. Proc ASH 2014;Abstract 501.

Dr Moskowitz is Clinical Director of the Division of Hematologic Oncology, Attending Physician for Lymphoma and Adult BMT Services, Member of Memorial Sloan Kettering Cancer Center and Professor of Medicine at the Weill Medical College of Cornell University in New York, New York.